StreetInsider.com News Articles

Form 6-K Optimi Health Corp. For: Sep 23

Wed, 23 Sep 2026 13:18:00 -0400

si-local-file:///var/storage/secattach/20260923/27095889.html

Optimi Health completes psilocybin batch for trial and Australia supply

Wed, 23 Sep 2026 09:00:58 -0400

Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI) announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured at its cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence.

The batch will serve two purposes: supplying a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD), and fulfilling commercial orders from licensed clinics in Australia.

The Phase 2 trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose. Patient dosing is expected to be completed by the end of 2027.

Optimi Health completes psilocybin batch for trial and Australia supply

Wed, 23 Sep 2026 09:00:58 -0400

The Phase 2 trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose. Patient dosing is expected to be completed by the end of 2027.

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Wed, 23 Sep 2026 09:00:00 -0400

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company’s cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The batch will supply the recently announced Phase 2 clinical trial of psilocybin-assisted therapy evaluating psilocybin-assisted therapy in the treatment of major depressive disorder (“MDD”)

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Wed, 23 Sep 2026 09:00:00 -0400

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Wed, 23 Sep 2026 09:00:00 -0400

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Wed, 23 Sep 2026 09:00:00 -0400

Optimi Health names Dr. Michael Blough as chief clinical officer

Tue, 22 Sep 2026 09:03:00 -0400

Optimi Health Corp. (NASDAQ: OPTH) has appointed Michael Blough, Ph.D., as Chief Clinical Development Officer, a newly created position at the Vancouver-based pharmaceutical company.

Dr. Blough brings more than 20 years of research experience, including leading Health Canada-authorized clinical trials involving psilocybin and MDMA for mental health conditions. He has collaborated with Optimi on clinical trial applications since 2022. He has also published over 30 peer-reviewed papers on glioblastoma and previously led a seven-year national research initiative funded by the Terry Fox Research Institute.

In his new role, Dr. Blough will oversee Optimi's clinical development strategy, including a planned Phase 2 trial

Optimi Health names Dr. Michael Blough as chief clinical officer

Tue, 22 Sep 2026 09:03:00 -0400

Optimi Health Corp. (NASDAQ: OPTH) has appointed Michael Blough, Ph.D., as Chief Clinical Development Officer, a newly created position at the Vancouver-based pharmaceutical company.

In his new role, Dr. Blough will oversee Optimi's clinical development strategy, including a planned Phase 2 trial

Form 6-K Optimi Health Corp. For: Sep 22

Tue, 22 Sep 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260922/27088583.html

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Tue, 22 Sep 2026 09:00:00 -0400

VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D., as Chief Clinical Development Officer.

Dr. Blough has significant experience leading Health Canada-authorized clinical trials and has worked with Optimi on clinical trial applications since 2022. In this newly created position, he will oversee Optimi’s clinical development strategy and related operations. This includes the Company’s planned Phase 2 clinical trial evaluating naturally derived psilocybin-assisted psychotherapy to

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Tue, 22 Sep 2026 09:00:00 -0400

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Tue, 22 Sep 2026 09:00:00 -0400

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Tue, 22 Sep 2026 09:00:00 -0400

Optimi Health plans Phase 3 MDMA-assisted therapy trial for PTSD

Wed, 16 Sep 2026 08:25:15 -0400

Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder, with the trial expected to begin in 2027.

The trial is designed to enroll up to 100 participants across multiple sites in Canada. Enrollment will focus on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters, and healthcare workers.

Participants will receive the company's synthetic MDMA HCl in two dosage formats during two supervised sessions combined with psychotherapy, spaced several weeks apart. The primary efficacy endpoint will be change in the Clinician-Administered PTSD

Optimi Health plans Phase 3 MDMA-assisted therapy trial for PTSD

Wed, 16 Sep 2026 08:25:15 -0400

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder